<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01871402</url>
  </required_header>
  <id_info>
    <org_study_id>000-0551-304</org_study_id>
    <nct_id>NCT01871402</nct_id>
  </id_info>
  <brief_title>A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind, Parallel Group Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 3 study has been designed to determine and compare the efficacy and safety of
      000-0551 Lotion and Vehicle Lotion applied twice daily for two weeks in subjects with plaque
      psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Subjects Rated a &quot;Treatment Success&quot; Based on the Investigator's Global Assessment (IGA)</measure>
    <time_frame>Day 15</time_frame>
    <description>The IGA score is a static evaluation of the overall or &quot;average&quot; degree of severity of a subject's disease, taking into account all of the subject's psoriatic lesions. &quot;Treatment success&quot; is defined as a score of 0 or 1 representing &quot;cleared&quot; or &quot;almost cleared&quot; at Day 15 with at least a two grade decrease in severity score relative to Baseline. IGA is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe/very severe).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects Rated a &quot;Treatment Success&quot; for Each of the Clinical Signs of Psoriasis (Scaling, Erythema and Plaque Elevation)</measure>
    <time_frame>Day 15</time_frame>
    <description>A static assessment of the overall or &quot;average&quot; degree of severity of each of three key characteristics present within all of the subject's psoriatic lesions. &quot;Treatment success&quot; is defined as a score of 0 or 1 representing &quot;cleared&quot; or &quot;almost cleared&quot; at Day 15 with at least a two grade decrease in severity score relative to Baseline. Each clinical sign of psoriasis is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe/very severe).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Proportion of Subjects With IGA &quot;Treatment Success&quot; at Day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>Interim analysis of IGA. &quot;Treatment success&quot; and IGA as defined in the primary outcome measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Proportion of Subjects Rated a &quot;Treatment Success&quot; for Each of the Clinical Signs of Psoriasis at Day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>Interim analysis of clinical signs of psoriasis (scaling, erythema and plaque elevation). &quot;Treatment success&quot; and clinical signs as defined in the secondary outcome measure.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change From Baseline in Pruritus Score at Day 15</measure>
    <time_frame>Baseline and Day 15</time_frame>
    <description>Pruritus scale will be used to assess the subjective and multidimensional experience of the subject's pruritus (itching) during the previous two weeks at Baseline and Day 15. Possible scores range from 5 (no pruritus) to 25 (most severe pruritus).</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in % Body Surface Area (BSA) With Active Psoriasis at Days 8 and 15</measure>
    <time_frame>Baseline, Day 8 and Day 15</time_frame>
    <description>The investigator will use the assumption that 1% BSA is approximately equal to the surface area of the subject's palm and fingers, with the fingers extended yet grouped together, creating a flat oval-like surface area.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">221</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Active Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical lotion, applied twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical lotion, applied twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>000-0551 Lotion</intervention_name>
    <arm_group_label>Active Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Lotion</intervention_name>
    <arm_group_label>Vehicle Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject has a clinical diagnosis of stable plaque psoriasis involving a minimum of 2%
             and no more than 12% affected body surface area.

          -  Subject has an Investigator's Global Assessment (IGA) score of at least three
             (moderate) at study start.

          -  If subject is a woman of childbearing potential, she must have a negative urine
             pregnancy test and agree to use an effective form of birth control for the duration of
             the study.

        Exclusion Criteria:

          -  Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.

          -  Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.

          -  Subject has used any phototherapy (including laser), photo-chemotherapy or other forms
             of photo based therapy for the treatment of their psoriasis within 30 days prior to
             study start.

          -  Subject has used any systemic methotrexate, retinoids, systemic corticosteroids
             [including intralesional, intra-articular, and intramuscular corticosteroids],
             cyclosporine or analogous products within 90 days prior to study start.

          -  Subject has used any systemic biologic therapy (i.e., FDA-approved or experimental
             therapy) within five half-lives of the biologic prior to study start.

          -  Subject had prolonged exposure to natural or artificial sources of ultraviolet
             radiation within 30 days prior to study start or is intending to have such exposure
             during the study.

          -  Subject has used topical body (excluding the scalp) psoriasis therapy (including coal
             tar, anthralin, steroids, retinoids, vitamin D analogs) within 14 days prior to study
             start.

          -  Subject has used emollients/moisturizers on areas to be treated within four hours
             prior to clinical evaluation at study start.

          -  Subject is currently using lithium or Plaquenil (hydroxychloroquine).

          -  Subject is currently using a beta-blocking medication (e.g., propanolol) or
             angiotensin converting enzyme (ACE) inhibitor at a dose that has not been stabilized.

          -  Subject is pregnant, lactating, or is planning to become pregnant during the study.

          -  Subject is currently enrolled in an investigational drug or device study.

          -  Subject has used an investigational drug or investigational device treatment within 30
             days prior to study start.

          -  Subject has been previously enrolled in this study and treated with a test article.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Syd Dromgoole, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Therapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research, Inc.</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSD Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altman Dermatology Associates</name>
      <address>
        <city>Arlington Heights</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilmington Dermatology Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Medical Research Center, PC</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Partners, LLC</name>
      <address>
        <city>Johnston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Across America</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Clinical Research, Inc.</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2013</study_first_posted>
  <results_first_submitted>March 10, 2016</results_first_submitted>
  <results_first_submitted_qc>March 10, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 11, 2016</results_first_posted>
  <disposition_first_submitted>February 13, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>February 13, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">March 4, 2015</disposition_first_posted>
  <last_update_submitted>April 11, 2016</last_update_submitted>
  <last_update_submitted_qc>April 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <keyword>lotion</keyword>
  <keyword>investigator's global assessment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment period: May 2013 to December 2013
The location of clinical sites included dermatology clinics and clinical research centers.</recruitment_details>
      <pre_assignment_details>All subjects who met the entry criteria were randomized and enrolled into the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Active Arm</title>
          <description>Topical lotion, applied twice daily
000-0551 Lotion</description>
        </group>
        <group group_id="P2">
          <title>Vehicle Arm</title>
          <description>Topical lotion, applied twice daily
Vehicle Lotion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="111"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="109"/>
                <participants group_id="P2" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Arm</title>
          <description>Topical lotion, applied twice daily
000-0551 Lotion</description>
        </group>
        <group group_id="B2">
          <title>Vehicle Arm</title>
          <description>Topical lotion, applied twice daily
Vehicle Lotion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="110"/>
            <count group_id="B2" value="111"/>
            <count group_id="B3" value="221"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.9" spread="12.28"/>
                    <measurement group_id="B2" value="50.8" spread="14.15"/>
                    <measurement group_id="B3" value="51.8" spread="13.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="96"/>
                    <measurement group_id="B3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="88"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="111"/>
                    <measurement group_id="B3" value="221"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Subjects Rated a &quot;Treatment Success&quot; Based on the Investigator's Global Assessment (IGA)</title>
        <description>The IGA score is a static evaluation of the overall or &quot;average&quot; degree of severity of a subject's disease, taking into account all of the subject's psoriatic lesions. &quot;Treatment success&quot; is defined as a score of 0 or 1 representing &quot;cleared&quot; or &quot;almost cleared&quot; at Day 15 with at least a two grade decrease in severity score relative to Baseline. IGA is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe/very severe).</description>
        <time_frame>Day 15</time_frame>
        <population>Analysis shown is based on the Intent-to-Treat population, defined as all enrolled participants who were randomized and applied at least one dose of the test article.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>Topical lotion, applied twice daily
000-0551 Lotion</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Arm</title>
            <description>Topical lotion, applied twice daily
Vehicle Lotion</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Rated a &quot;Treatment Success&quot; Based on the Investigator's Global Assessment (IGA)</title>
          <description>The IGA score is a static evaluation of the overall or &quot;average&quot; degree of severity of a subject's disease, taking into account all of the subject's psoriatic lesions. &quot;Treatment success&quot; is defined as a score of 0 or 1 representing &quot;cleared&quot; or &quot;almost cleared&quot; at Day 15 with at least a two grade decrease in severity score relative to Baseline. IGA is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe/very severe).</description>
          <population>Analysis shown is based on the Intent-to-Treat population, defined as all enrolled participants who were randomized and applied at least one dose of the test article.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.5"/>
                    <measurement group_id="O2" value="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Treatment groups were compared with respect to the proportions of subjects with “treatment success” at Day 15 using the Cochran-Mantel-Haenszel (CMH) test stratified by analysis center.</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Multiple imputation was used to impute missing data from the ITT population.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects Rated a &quot;Treatment Success&quot; for Each of the Clinical Signs of Psoriasis (Scaling, Erythema and Plaque Elevation)</title>
        <description>A static assessment of the overall or “average” degree of severity of each of three key characteristics present within all of the subject’s psoriatic lesions. &quot;Treatment success&quot; is defined as a score of 0 or 1 representing &quot;cleared&quot; or &quot;almost cleared&quot; at Day 15 with at least a two grade decrease in severity score relative to Baseline. Each clinical sign of psoriasis is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe/very severe).</description>
        <time_frame>Day 15</time_frame>
        <population>Analysis shown is based on the ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>Topical lotion, applied twice daily
000-0551 Lotion</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Arm</title>
            <description>Topical lotion, applied twice daily
Vehicle Lotion</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Rated a &quot;Treatment Success&quot; for Each of the Clinical Signs of Psoriasis (Scaling, Erythema and Plaque Elevation)</title>
          <description>A static assessment of the overall or “average” degree of severity of each of three key characteristics present within all of the subject’s psoriatic lesions. &quot;Treatment success&quot; is defined as a score of 0 or 1 representing &quot;cleared&quot; or &quot;almost cleared&quot; at Day 15 with at least a two grade decrease in severity score relative to Baseline. Each clinical sign of psoriasis is measured on a 5-point scale, ranging from 0 (clear) to 4 (severe/very severe).</description>
          <population>Analysis shown is based on the ITT population.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="110"/>
                <count group_id="O2" value="111"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scaling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.5"/>
                    <measurement group_id="O2" value="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.4"/>
                    <measurement group_id="O2" value="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plaque Elevation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.5"/>
                    <measurement group_id="O2" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment groups were compared with respect to each of the clinical signs of psoriasis (scaling, erythema, and plaque elevation).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Statistical significance (&lt;0.001) was achieved for each of the clinical signs of psoriasis (scaling, erythema, and plaque elevation).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Missing data was imputed as treatment failure.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects With IGA “Treatment Success” at Day 8</title>
        <description>Interim analysis of IGA. &quot;Treatment success&quot; and IGA as defined in the primary outcome measure.</description>
        <time_frame>Day 8</time_frame>
        <population>Analysis shown is based on the ITT population. Only participants with observed values are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>Topical lotion, applied twice daily
000-0551 Lotion</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Arm</title>
            <description>Topical lotion, applied twice daily
Vehicle Lotion</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With IGA “Treatment Success” at Day 8</title>
          <description>Interim analysis of IGA. &quot;Treatment success&quot; and IGA as defined in the primary outcome measure.</description>
          <population>Analysis shown is based on the ITT population. Only participants with observed values are reported.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Proportion of Subjects Rated a “Treatment Success” for Each of the Clinical Signs of Psoriasis at Day 8</title>
        <description>Interim analysis of clinical signs of psoriasis (scaling, erythema and plaque elevation). &quot;Treatment success&quot; and clinical signs as defined in the secondary outcome measure.</description>
        <time_frame>Day 8</time_frame>
        <population>Analysis shown is based on the ITT population. Only participants with observed values are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>Topical lotion, applied twice daily
000-0551 Lotion</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Arm</title>
            <description>Topical lotion, applied twice daily
Vehicle Lotion</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects Rated a “Treatment Success” for Each of the Clinical Signs of Psoriasis at Day 8</title>
          <description>Interim analysis of clinical signs of psoriasis (scaling, erythema and plaque elevation). &quot;Treatment success&quot; and clinical signs as defined in the secondary outcome measure.</description>
          <population>Analysis shown is based on the ITT population. Only participants with observed values are reported.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Scaling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9"/>
                    <measurement group_id="O2" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.8"/>
                    <measurement group_id="O2" value="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plaque Elevation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.1"/>
                    <measurement group_id="O2" value="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Treatment groups were compared with respect to each of the clinical signs of psoriasis (scaling, erythema, and plaque elevation).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Statistical significance (&lt;0.001) was achieved for each of the clinical signs of psoriasis (scaling, erythema, and plaque elevations).</p_value_desc>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change From Baseline in Pruritus Score at Day 15</title>
        <description>Pruritus scale will be used to assess the subjective and multidimensional experience of the subject’s pruritus (itching) during the previous two weeks at Baseline and Day 15. Possible scores range from 5 (no pruritus) to 25 (most severe pruritus).</description>
        <time_frame>Baseline and Day 15</time_frame>
        <population>Analysis shown is based on the ITT population. Only participants with observed values are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>Topical lotion, applied twice daily
000-0551 Lotion</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Arm</title>
            <description>Topical lotion, applied twice daily
Vehicle Lotion</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Pruritus Score at Day 15</title>
          <description>Pruritus scale will be used to assess the subjective and multidimensional experience of the subject’s pruritus (itching) during the previous two weeks at Baseline and Day 15. Possible scores range from 5 (no pruritus) to 25 (most severe pruritus).</description>
          <population>Analysis shown is based on the ITT population. Only participants with observed values are reported.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="3.46"/>
                    <measurement group_id="O2" value="-3.1" spread="3.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in % Body Surface Area (BSA) With Active Psoriasis at Days 8 and 15</title>
        <description>The investigator will use the assumption that 1% BSA is approximately equal to the surface area of the subject’s palm and fingers, with the fingers extended yet grouped together, creating a flat oval-like surface area.</description>
        <time_frame>Baseline, Day 8 and Day 15</time_frame>
        <population>Analysis shown is based on the ITT population at Days 8 and 15 and compared to baseline. Number of Participants Analyzed is at Day 15; at Day 8, N=109 (Active) and N=110 (Vehicle). Only participants with observed values are reported.</population>
        <group_list>
          <group group_id="O1">
            <title>Active Arm</title>
            <description>Topical lotion, applied twice daily
000-0551 Lotion</description>
          </group>
          <group group_id="O2">
            <title>Vehicle Arm</title>
            <description>Topical lotion, applied twice daily
Vehicle Lotion</description>
          </group>
        </group_list>
        <measure>
          <title>Change in % Body Surface Area (BSA) With Active Psoriasis at Days 8 and 15</title>
          <description>The investigator will use the assumption that 1% BSA is approximately equal to the surface area of the subject’s palm and fingers, with the fingers extended yet grouped together, creating a flat oval-like surface area.</description>
          <population>Analysis shown is based on the ITT population at Days 8 and 15 and compared to baseline. Number of Participants Analyzed is at Day 15; at Day 8, N=109 (Active) and N=110 (Vehicle). Only participants with observed values are reported.</population>
          <units>Change in %BSA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="109"/>
                <count group_id="O2" value="108"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.7" spread="1.59"/>
                    <measurement group_id="O2" value="-0.1" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="2.22"/>
                    <measurement group_id="O2" value="-0.2" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) were collected from study Day 1 (enrollment/first dose) to study completion (Day 15) or participant termination. AEs that continued beyond completion/termination were followed until resolution or stabilization.</time_frame>
      <desc>The Safety population included all subjects enrolled in the study who were dispensed the test article at least once; because the first dose of the test article was applied at the study site (Day 1), all enrolled subjects (N=221) were included in the safety population. Most AEs were mild in severity.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Arm</title>
          <description>Topical lotion, applied twice daily
000-0551 Lotion</description>
        </group>
        <group group_id="E2">
          <title>Vehicle Arm</title>
          <description>Topical lotion, applied twice daily
Vehicle Lotion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (16.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="110"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Application site erythema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Application site pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="110"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="111"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="110"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="111"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor has first right to publish pooled study data. In the event that such manuscript has not been submitted for publication within 12 months from study completion/termination at all participating sites, the PI shall have the right to single center publications provided they submit any data for presentation, oral or written, to the Sponsor for review 30 days prior to public disclosure. The PI may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research, Therapeutics, Inc.</name_or_title>
      <organization>Therapeutics, Inc.</organization>
      <phone>858-571-1800</phone>
      <email>clinicalresearch@therapeuticsinc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

